Depomed seeks court's help in orphan exclusivity fight after FDA shutout
This article was originally published in Scrip
Executive Summary
Depomed believes its postherpetic neuralgia (PHN) drug Gralise (gabapentin) is entitled to the seven years of orphan drug exclusivity the firm thinks it earned "as a matter of law" and is asking a federal court to ensure the US FDA grants it.